维普中文期刊产品整合服务
9篇 您的检索式:作者名="Fecto"
    题名 作者 年代 出处 被引量
1A novel de novo MFN2 mutation causing CMT2A with upper motor neuron signs显示文摘Ajroud-Driss S Fecto F Ajroud K 0,,:1
2FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyottophic lateral sclerosis显示文摘Deng H X Zhai H Bigio E H Yah J Fecto F Ajroud K Mishra M Ajroud-Driss S Hel 0,,06:1
3查看详情显示文摘Klein CJ Shi Y Fecto F 0,,:1
4A novel de novo MFN2 mutation causing CMT2A with upper motor neuron signs显示文摘Ajroud-Driss S Fecto F Ajroud K 2009Neurogenetics2009,10,4:1
5SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis显示文摘Fecto F Yan J Vemula SP 2011Arch Neurol2011,68,:1
6SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis显示文摘Fecto F Yan J Vemula S P Liu E Yang Y Chen W Zheng J G Shi Y Siddique N Arr 0,,11:1
7Mutation in the no- vel nuclear-encoded mitochondrial protein CHCHD10 in a fami- ly with autosomal dominant mitochondrial myopathy显示文摘Ajroud-Driss S Fecto F Ajroud K 2015Neu- rogenetics2015,16,1:1
8Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia显示文摘J. Yan H.-X. Deng N. Siddique F. Fecto W. Chen Y. Yang E. Liu S. Donkervoort J.G. Zheng Y. Shi K.B. Ahmeti B. Brooks W.K. Engel T. Siddique 2010Neurology2010,,9:1
9Signaling mechanisms mediated by G-protein coupled receptors in human platelets显示文摘AIM: The present study deals with the investigation of mechanisms involved in the synergistic interaction between epinephrine and arachidonic acid (AA). METHODS: Venous blood was taken from healthy human volunteers reported to be free of medications for one week. Platelet aggregation was monitored at 37oC using Dual-channel Lumi-aggregometer. The resulting aggregation was recorded for 5 min by the measurement of light transmission as a function of time. RESULTS: The data show that a synergism in platelet aggregation mediated by subthreshold concentrations of epinephrine (1 μmol/L) and AA (0.2 μmol/L) was inhibited by the α2-receptor antagonist (yohimbine, IC50=0.6 μmol/L) and an inhibitor of AA-cyclooxygenase (COX), indomethacin (IC50=0.25 μmol/L). In examining receptor influence on intraplatelet signalling pathways, it was found that the synergistic effect was inhibited by calcium channel blockers, verapamil (IC50=0.4 μmol/L) and diltiazem (IC50=2.5 μmol/L), as well as by low concentrations of inhibitors of phospholipase C (PLC) (U73122; IC50=0.2 μmol/L) and mitogens activated protein kinase (MAPK) (PD 98059; IC50=3.8 μmol/L). Herbimycin A, a specific inhibitor of tyrosine light chain kinase (TLCK), showed inhibition at IC50 value of 15 μmol/L, whereas chelerythrine, a protein kinase C (PKC) inhibitor, had no effect up to 20 μmol/L. CONCLUSION: These data suggest that synergism between epinephrine and AA in platelet aggregation is triggered through receptors coupled to G-protein, which in turn, activate PLC, COX, and MAP kinase-signaling pathways.Sheikh Arshad SAEED Huma RASHEED Faisal A Wahed FECTO Mohammad Ilyas ACHAKZAI Rahmat ALI John Dennis CONNOR Anwar-ul-Hassan GILANI 2004Acta Pharmacologica Sinica2004,25,7:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费